Results 211 to 220 of about 160,145 (308)

Post‐Transplant Bendamustine as a Platform for Immune Modulation After Allogeneic Hematopoietic Cell Transplantation

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 739-749, October 2026.
ABSTRACT Post‐transplant cyclophosphamide (PT‐CY) remains the standard of care for graft‐versus‐host disease (GvHD) prophylaxis in haploidentical hematopoietic cell transplantation (HCT), yet relapse, delayed immune reconstitution, infections, and organ toxicity represent persistent and clinically meaningful limitations.
Megan J. Cracchiolo   +2 more
wiley   +1 more source

Third Allogeneic Stem Cell Transplantation in Children: A Multicenter Analysis From the Spanish GETH‐TC Pediatric Group

open access: yesEuropean Journal of Haematology, Volume 117, Issue 4, Page 943-952, October 2026.
ABSTRACT Third allogeneic hematopoietic stem cell transplantation (HSCT3) is rarely performed in pediatric patients and is associated with high toxicity and mortality. Data on outcomes in this setting remain scarce. We conducted a retrospective multicenter study within the Spanish GETH‐TC Pediatric group including 29 children and adolescents who ...
Luisa Sisinni   +17 more
wiley   +1 more source

Clonal Hematopoiesis and CAR T Cell Therapy: From Biological Crosstalk to Clinical Implications

open access: yesInternational Journal of Laboratory Hematology, Volume 48, Issue 5, Page 961-971, October 2026.
ABSTRACT Clonal hematopoiesis (CH) is increasingly recognized as a significant biological phenomenon in aging and cancer, marked by the expansion of hematopoietic stem and progenitor cells harboring somatic mutations in genes associated with myeloid neoplasms.
Wei Du   +4 more
wiley   +1 more source

Genomic Medicine Sweden: Advancing precision medicine at the national level

open access: yesJournal of Internal Medicine, Volume 300, Issue 4, Page 397-419, October 2026.
Abstract High‐throughput sequencing has transformed clinical diagnostics of rare diseases (RD), cancer and infectious diseases by enabling the identification of disease‐causing genetic alterations and facilitating individualised treatment and care.
Anders Edsjö   +58 more
wiley   +1 more source

Case report: Eosinophilia as a rare symptom and primary sign of acute lymphoblastic leukemia with translocation (5;14)(q31;q32). [PDF]

open access: yesFront Oncol
van Heteren P   +12 more
europepmc   +1 more source

The Efficacy of Pharmacotherapy Intervention on Anthropometric Outcomes in Survivors of Childhood Brain Tumors: An Updated Systematic Review and Meta‐Analysis

open access: yesObesity Reviews, Volume 27, Issue 10, October 2026.
ABSTRACT Introduction Many survivors of childhood brain tumors face long‐term adverse health outcomes like obesity. Uncertainties surround the effect of interventions to manage obesity‐related outcomes in survivors of childhood brain tumors. The goal of this updated systematic review and meta‐analysis was to provide the best estimate of the treatment ...
David Hart   +11 more
wiley   +1 more source

Generation of Allogeneic CAR‐T Circumvents Functional Deficits in Patient‐Derived Autologous Product for Glioblastoma

open access: yesInternational Journal of Cancer, Volume 159, Issue 6, Page 1521-1534, 15 September 2026.
Clinical trials of chimeric antigen receptor T‐cell (CAR‐T) therapies in glioblastoma have shown limited clinical benefits. Whether this may be explained by the basal quality of CAR‐T products, which are currently generated using patient, autologous T‐cells, has been little explored.
Sabra K. Salim   +22 more
wiley   +1 more source

Home - About - Disclaimer - Privacy